Provided by Tiger Trade Technology Pte. Ltd.

Adaptive Biotechnologies Corp

27.93
-0.1200-0.43%
Post-market: 27.89-0.0379-0.14%19:52 EST
Volume:2.48M
Turnover:69.05M
Market Cap:4.52B
PE:-61.66
High:28.23
Open:27.43
Low:27.15
Close:28.05
52wk High:32.21
52wk Low:12.00
Shares:161.88M
Float Shares:128.00M
Volume Ratio:1.15
T/O Rate:1.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4530
EPS(LYR):-0.3922
ROE:-36.44%
ROA:-5.13%
PB:25.66
PE(LYR):-71.22

Loading ...

Adaptive Biotechnologies' clonoSEQ Features in About 100 Abstracts at ASH 2026

Reuters
·
Nov 18

Guggenheim Remains a Buy on Adaptive Biotechnologies (ADPT)

TIPRANKS
·
Nov 16

Adaptive Biotechnologies President and COO Julie Rubinstein Sells $1.05 Million in Common Shares

Reuters
·
Nov 14

How Investors May Respond To Adaptive Biotechnologies (ADPT) DNA Sequencing Spotlight

Simply Wall St.
·
Nov 13

Adaptive Biotechnologies (ADPT) Lands In $17.1 Billion DNA Sequencing Market Report

Simply Wall St.
·
Nov 12

Adaptive Biotechnologies President and COO Julie Rubinstein Reports Sale of $708,557.50 in Common Shares

Reuters
·
Nov 11

Adaptive Biotechnologies Participates in Jefferies and Piper Sandler Healthcare Conferences

Reuters
·
Nov 11

Adaptive Biotechnologies is Maintained at Buy by Guggenheim

Dow Jones
·
Nov 10

Adaptive Biotechnologies (ADPT) Stock Looks Reasonable As Cash Flow Recovery Takes Shape

Simply Wall St.
·
Nov 10

Adaptive Biotechnologies Corporation : Piper Sandler Raises Target Price to $35 from $27.5

THOMSON REUTERS
·
Nov 10

US Research Roundup-Autodesk, Metlife, Rollins

Reuters
·
Nov 09

Is Adaptive Biotechnologies (ADPT) Still Below Fair Value On Mixed Q3 Results?

Simply Wall St.
·
Nov 09

Adaptive Biotechnologies Corporation : JP Morgan Raises Target Price to $35 from $30

THOMSON REUTERS
·
Nov 09

Adaptive Biotechnologies President and COO Julie Rubinstein Reports Disposal of $954,441.88 in Common Shares

Reuters
·
Nov 07

Biodesix Q3 Revenue Misses Estimates on Seasonality Impact, Project Delays

Reuters
·
Nov 06

Quarterly Sales Slip Might Change The Case For Investing In Adaptive Biotechnologies (ADPT)

Simply Wall St.
·
Nov 05

Adaptive Biotechnologies Raises FY 2026 MRD Revenue Forecast to $276 Million-$286 Million

Reuters
·
Nov 05

Adaptive Biotechnologies Corporation Reports Results for the Quarter Ended September 30 - Earnings Summary

Reuters
·
Nov 05

Adaptive Biotechnologies Q3 Net Income Drops 71% to $2.81 Million

Reuters
·
Nov 05

Adaptive Biotechnologies Q3 EPS USD 0.02

Reuters
·
Nov 05